A pan-European  team of lawyers from Baker McKenzie advised specialty pharmaceutical company Cosmo Pharmaceuticals N.V. ("Cosmo") on its successful debut offering in the Eurobond markets - a placement of EUR 175 million senior unsecured convertible bonds.

Cosmo is a specialty pharmaceutical company that aims to become a global leader in the field of optimized therapies for selected Gastrointestinal Disorders and Endoscopic Procedures. The Company’s proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as Ulcerative Colitis and Crohn’s Disease, and Colon Infections. Cosmo explains that the net proceeds from this transaction will be used for general purposes, potential acquisitions and in-licensing transactions.

The Bonds will have a maturity of 5 years and will be convertible into ordinary shares of SIX Swiss Exchange listed Cosmo, sourced from existing authorized share capital.

A cross-border team of Baker McKenzie lawyers from its London, Zurich, Amsterdam and Luxembourg offices advised Cosmo, led by partners Matthias Courvoisier in Zurich and Michael Doran in London working with partner Henk Arnold Sijnja and legal director Rebecca Kuijpers-Zimmerman in Amsterdam, partner Laurent Fessmann and associate Alexis Bouvet in Luxembourg and associate Simon Foster and trainee Nicole Fitzpatrick in London.

Speaking after the transaction completed, Matthias Courvoisier, who leads the Baker McKenzie Capital Markets Practice  in Zurich, and who advised Cosmo on its SIX Swiss Exchange share  listing in 2007, said, "We are proud to have executed and delivered for Cosmo on this transaction, in a very tight timeframe. This convertible bond deal shows the strength of our European capital markets team, as the industry experiences one of the longest and most active financing windows in recent years."

Jefferies, Credit Suisse and Berenberg acted as joint bookrunners for the Bonds.
Explore Our Newsroom